NEJM in Review — August 20, 2026

This week’s practice-changer is MARCH — a large factorial trial that finds mucoactive agents (carbocisteine and hypertonic saline) neither shorten mechanical ventilation nor improve outcomes in acute respiratory failure, and both cause significant harm. The editorial: “time to move away from routine use.” SYNCHRONIZE-1 introduces survodutide, the first dual glucagon/GLP-1 receptor agonist with phase 3 obesity data, notable for its distinctive liver-fat reduction. A comprehensive MPN review delivers board-relevant pearls on JAK2 zygosity and CALR mutation types, and the MGH case illustrates disseminated CMV facilitating cryptococcosis via the “net state of immunosuppression” framework. Two lower-yield RCTs — pediatric wheezing (AZ-SWED) and EGFR exon 20 NSCLC (WU-KONG28) — are summarized for awareness.

PULM / CRITICAL CAREMARCH✓ HIGH YIELD · IM

Carbocisteine or Hypertonic Saline for Acute Respiratory Failure

In mechanically ventilated adults with acute hypoxemic respiratory failure, do mucoactive agents (carbocisteine or hypertonic saline) vs no mucoactive reduce the duration of mechanical ventilation?

Population: 1,956 adults in 26 French ICUs, mechanically ventilated ≤24 h for acute hypoxemic respiratory failure. 2×2 factorial, open-label, phase 3. Mean age 63, 66% men, 43% ARDS. Excluded: chronic airway disease with preexisting mucoactive therapy.
Intervention: Carbocisteine 750 mg TID enterally, and/or hypertonic saline 6–7% 4 mL QID via nebulization.
Comparison: No mucoactive agent (open-label; factorial design produces four groups).
Outcome: Both NEGATIVE for the primary endpoint. Harms: carbocisteine → GI bleeding 1.4% vs 0.2% (RR 6.51, P=0.01); HTS → bronchoconstriction 2.4% vs 0.4% (RR 5.73) and hypoxemia during nebulization 4.1% vs 0.3% (RR 13.29, P<0.001).

Clinical takeaway: Neither carbocisteine nor hypertonic saline shortened mechanical ventilation, and both caused clinically significant harm. The editorial (La Vita & Hardin) concludes: “time to move away from the routine use of mucoactive agents in patients with acute respiratory failure.” Caveats: open-label; excluded patients already on mucoactive therapy for chronic airway disease; “difficult-to-manage secretions” was not standardized.

ENDOCRINOLOGYSYNCHRONIZE-1✓ HIGH YIELD · IM

Survodutide Once Weekly for Obesity

In adults with obesity (BMI ≥30, or ≥27 with a complication) without diabetes, does survodutide — a dual glucagon/GLP-1 receptor agonist — vs placebo achieve clinically significant weight loss at 76 weeks?

Population: 725 adults with BMI ≥30 (or ≥27 + ≥1 complication), without diabetes. Mean BMI ~38, mean age ~48, ~68% women. Double-blind, phase 3. Excluded: prior bariatric surgery, T2DM.
Intervention: Survodutide 3.6 mg or 6.0 mg SC weekly (titrated over 20 wk).
Comparison: Placebo SC weekly.
Outcome: Weight change at 76 wk: −12.2% (3.6 mg), −13.0% (6.0 mg) vs −5.4% placebo (P<0.001). ≥5% weight loss: 73%, 72% vs 46%. MRI subgroup: 6.0 mg reduced liver fat 63% vs 25% placebo, visceral fat 34% vs 12%. GI AEs: up to 90%; discontinuation for GI: 18–20%.

Clinical takeaway: Survodutide is the first dual GCG/GLP-1R agonist with phase 3 data in obesity. The glucagon-receptor component boosts energy expenditure and hepatic lipid oxidation — hence the distinctive liver-fat reduction. Weight loss (~13%) is less than semaglutide (~15% in STEP 1) or tirzepatide (~20% in SURMOUNT-1), but the liver-fat signal may position survodutide for MASLD/MASH. GI tolerability (up to 20% discontinuation) remains the major barrier.

ALLERGY / IMMUNOLOGYAZ-SWED⚠ LOWER YIELD · PEDIATRIC

Azithromycin for Preschoolers with Wheezing in the Emergency Department

In preschoolers (18–59 months) with moderate-to-severe wheezing in the ED, does azithromycin vs placebo improve symptom scores?

Population: 840 children aged 18–59 mo in 16 US EDs with moderate-to-severe wheezing. Stratified by airway bacterial detection. Stopped for futility.
Intervention: Azithromycin 12 mg/kg/day orally ×5 days.
Comparison: Placebo.
Outcome: ADYC scores: bacteria-positive 9.59 vs 9.72 (P=0.70); bacteria-negative 9.30 vs 9.10 (P=0.69) — no difference. Bacterial clearance 58.7% vs 11.4% but no clinical benefit.

Clinical takeaway: Azithromycin cleared bacteria but did not improve symptoms in established ED-level preschool wheezing. The editorial (Bush & Saglani) notes prior trials showed benefit only when given early/outpatient — timing and severity matter. Calls for phenotyping acute wheezing with point-of-care eosinophil counts. Pediatric-specific with no direct internist application.

HEME/ONCWU-KONG28⚠ LOWER YIELD · NARROW ONC

Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

In untreated advanced nonsquamous NSCLC with EGFR exon 20 insertions, does first-line sunvozertinib vs carboplatin-pemetrexed improve PFS?

Population: 324 patients in 15 countries with advanced nonsquamous NSCLC with EGFR exon 20 insertion mutations, treatment-naive. Phase 3, open-label.
Intervention: Sunvozertinib 300 mg PO daily.
Comparison: Carboplatin-pemetrexed (≤4 cycles) + pemetrexed maintenance.
Outcome: PFS: 10.3 vs 7.5 mo (HR 0.65; P<0.001). ORR 58.9% vs 31.1%. OS immature. Grade ≥3 AEs 75.5% vs 56.7% (CK elevation 20.9%, diarrhea 14.1%). 90.2% crossover.

Clinical takeaway: First positive phase 3 trial for a targeted agent in untreated EGFR exon 20 insertion NSCLC (2–3% of all NSCLC). PFS benefit is modest (2.8 mo), OS immature, 90% crossover. A thoracic-oncology decision.

Review Article

HEMATOLOGY✓ HIGH YIELD · IM

Myeloproliferative Neoplasms • JAK2 V617F zygosity determines phenotype: heterozygosity favors megakaryocyte differentiation → ET; homozygosity (from mitotic recombination on 9p) favors erythroid differentiation → PV. One mutation, two diseases. • CALR type 1 (52-bp deletion) → most common, more progression to myelofibrosis. Type 2 (5-bp insertion) → rarer, worse overall prognosis. Mutant CALR acts as a “rogue chaperone” + cytokine, activating MPL independently. • Driver mutations arise decades before clinical MPN (JAK2 ~25 yr, CALR ~15 yr). >90% of MPNs carry JAK2, CALR, or MPL mutations. Post-MPN AML: median survival 3–5 months. • Emerging therapies: INCA033989 (anti-mutant CALR antibody, >90% response in refractory ET), INCB160058 (selective JAK2 V617F JH2 inhibitor), AJ1-11095 (type II JAK2 inhibitor for ruxolitinib-resistant MF).

Case Records of the MGH

INFECTIOUS DISEASE✓ HIGH YIELD · IM/ID

Case 24-2026: A 74-Year-Old Man with Dyspnea, Proximal Muscle Weakness, and Hypoxemia

Key learning point: A 74-year-old man on prednisone + mycophenolate for myasthenia gravis presented with progressive weakness, pancytopenia, hepatocellular injury, and a tongue ulcer. Diagnosis: disseminated CMV reactivation (viral load 6.27 million IU/mL) followed by disseminated cryptococcosis (CrAg >1:2560, blood + CSF culture positive). CMV downregulates CD36 and SCARF1 on monocytes, impairing phagocytic clearance of Cryptococcus — illustrating one opportunistic infection facilitating another via the “net state of immunosuppression” framework. CMV oral ulcers arise from vascular endothelial infection with mucosal ischemic necrosis (distinct from HSV’s direct epithelial cytopathic effect). The patient died despite treatment.

DOIs this issue: NEJMoa2603406 (MARCH) · NEJMoa2516505 (AZ-SWED) · NEJMoa2604461 (WU-KONG28) · NEJMoa2600751 (SYNCHRONIZE-1) · NEJMra2507867 (MPN Review) · NEJMcpc2603179 (Case 24-2026)

Trial registrations: ISRCTN17683568 (MARCH) · NCT04669288 (AZ-SWED) · NCT05668988 (WU-KONG28) · NCT06066515 (SYNCHRONIZE-1)

All summaries are original paraphrase for personal study; no publisher text is reproduced. Full articles available at nejm.org via institutional or personal access. Anki cards attached for high-yield items.